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Abstract: The present study was designed to investigate the in vitro antiproliferative 
activity against ten human cancer cell lines of a series of galloyl derivatives bearing 
substituted-1,3,4-oxadiazole and carbohydrazide moieties. The compounds were also 
assessed in an in silico study of the absorption, distribution, metabolism and excretion 
(ADME) in the human body using Lipinski’s parameters, the topological polar surface area 
(TPSA) and percentage of absorption (%ABS). In general, the introduction of  
N'-(substituted)-arylidene galloyl hydrazides 4–8 showed a moderate antitumor activity, 
while the 2-methylthio- and 2-thioxo-1,3,4-oxadiazol-5-yl derivatives 9 and 10 led to 
increased inhibition of cancer cell proliferation. The precursor compound methyl gallate 2 
and the intermediary galloyl hydrazide 3 showed greater antiproliferative activity with GI50 
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values < 5.54 µM against all human tumor cell lines tested. A higher inhibition effect 
against ovarian cancer (OVCAR-3) (GI50 = 0.05–5.98 µM) was also shown, with 
compounds 2, 3, 9 and 10 with GI50 ≤ 0.89 µM standing out in this respect. The in silico 
study revealed that the compounds showed good intestinal absorption. 
Keywords: galloyl; hydrazide; oxadiazole; antiproliferative activity; in silico study 
 
1. Introduction 
Gallic acid (3,4,5-trihydroxybenzoic acid) is a polyphenol that possesses a wide spectrum of 
important pharmacological properties. In particular, gallic acid affects several pharmacological and 
biochemical pathways and has strong antioxidant [1,2], anti-inflammatory [3], antimutagenic and 
anticancer properties [4–6], showing selective cytotoxicity against a variety of tumor cells and much 
less toxicity against normal cells [7–15]. 
Studies with a variety of synthetic galloyl derivatives have demonstrated the influence of 
substituents on cytotoxic activity, e.g., digalloylresveratrol shows induction of apoptosis and necrosis 
in HT-29 colon cancer cells and HL-60 human promyelocytic leukemia cells, and gallic acid esters 
show inhibition of cancer cell proliferation [14,16–23]. Appropriate substituents in the galloyl group 
positions could lead to more potent compounds. 
The isolation of methyl gallate from the methanol extract of Schinus terebinthifolius leaves by our 
research group (data not shown) and the biological potential of the galloyl group directed us to develop 
derivatives as antitumor agents. Mannich bases of oxadiazoles and carbohydrazides possess important 
activities, including anticancer functions [24–27] and our prior studies showed that introducing  
1,3,4-oxadiazole and carbohydrazide units at the C-3 position of the β-carboline derivatives led to 
significant antitumor action [28–30]. As such, we proposed the synthesis and in vitro antiproliferative 
activity evaluation of a series of galloyl derivatives bearing the substituted-1,3,4-oxadiazole and 
carbohydrazide moiety at position C-1, expecting that the incorporation of these substituent may 
improve the antitumor activities of the galloyl group. Herein, the synthesis of 2-methylthio- and  
2-thioxo-1,3,4-oxadiazol-5-yl derivatives is reported for the first time. Additionally, an in silico study 
of the absorption, distribution, metabolism, and excretion (ADME) properties of the compounds was 
performed by investigating their match of Lipinski’s rules, topological polar surface area (TPSA) and 
percentage of absorption (%ABS). In silico ADME is currently used widely to determine whether it is 
possible for a drug candidate to reach its site of action. 
2. Results and Discussion 
2.1. Chemistry 
The synthetic route for the preparation of the galloyl derivatives is presented in Scheme 1. Methyl 
gallate (2) was prepared by esterification of the corresponding carboxylic acid 1 with methanol and 
sulfuric acid [31]. The reaction of methyl gallate with hydrazine hydrate yielded the galloyl hydrazide 3. 
Condensation of the hydrazide 3 with aromatic aldehydes (benzaldehyde, 4-dimethylaminobenzaldehyde, 
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4-nitrobenzaldehyde, 4-methoxybenzaldehyde and 4-hydroxybenzaldehyde), in ethanol heated at 
reflux, yielded the N'-(substituted)-arylidenegalloyl hydrazides 4–8, respectively. The IR and 1H-NMR 
spectroscopic data of these compounds were consistent with the related literature and the experimental 
conditions and yields for the reaction were satisfactory [32]. 
(4)   R= H 
(5)   R= 4-N(CH3)2
(6)   R= 4-NO2
(7)   R= 4-OCH3
(8)   R= 4-OH 
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Reagents and conditions: (a) MeOH, H2SO4, reflux, 48 h; 85%; (b) NH2NH2·H2O, EtOH, reflux, 48 h; 74%;  
(c) RCHO, EtOH, H2SO4 (cat), reflux, 36 h; 74%–80%; (d) CS2/KOH, EtOH, reflux, 48 h, acidified dilute 
HCl; (e) MeI, K2CO3, THF, rt, 48 h. 
Scheme 1. Synthetic route for the preparation of the galloyl derivatives. 
For preparation of new derivatives of galloyl-2-thioxo-1,3,4-oxadiazole (9), the key intermediate 3 
was subjected to a reaction with carbon disulfide in the presence of KOH and ethanol heated at reflux. 
The 1,3,4-oxadiazolyl 9 was subsequently S-methylated with methyl iodide in the presence of K2CO3 
at room temperature to yield afford the galloyl-2-methylthio-1,3,4-oxadiazole 10. 
The chemical structures of all compounds were confirmed by spectral data (1H- and 13C-NMR, IR, 
and MS) (see Section 3). The 1H-NMR spectra of N'-(substituted)-arylidene galloyl hydrazides 4–8 
displayed signals at δH 8.40 ppm integrating for one proton and δH 6.70–9.00 ppm, corresponding to 
the imine and aromatic hydrogens, respectively, of the (substituted-benzylidene) galloyl hydrazide 
group. The presence of this group was confirmed by the signals at δC 147–150 (C=N), 158–162 (C=O), 
and 110–135 ppm (aromatic carbons of R group) in the 13C-NMR spectra. 
The galloyl-2-thioxo-1,3,4-oxadiazole 9 may exist in a thione-thiol tautomeric structure, as 
indicated by the –NH and –SH proton signals at 13.7–14.1 ppm in the 1H-NMR spectrum, as a broad 
singlet integrating for one hydrogen each. In the solid state, these compounds are present in the thione 
(C=S) form, as indicated in their IR spectrum by the absence of the νs(S–H) absorption band at  
2500 cm−1 and the presence of two ν(C=S) absorption bands at 1230–1339 cm−1, which is 
characteristic for this class of compounds. The S-methylated derivative 10 was characterized by the 
presence of an addition signal at δH/δC 2.84/14.7 ppm, corresponding to the S-methyl group attached to 
the oxadiazole nucleus. 
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2.2. Antiproliferative Activity 
Three response parameters (GI50, TGI, and LC50) were calculated for each compound and cell line, 
and the results are summarized in Tables 1 and 2. 
Table 1. GI50 values (µM) for compounds 2–10 in ten tumor cell lines. 
Cancer Cell Lines 
 U251 MCF-7 NCI/ADR-RES 786-0 NCI-H460 PC-3 OVCAR-3 HT-29 K-562 HaCaT 
2 0.16 0.16 0.12 0.65 0.13 0.57 0.05 0.49 0.31 0.26 
3 1.11 0.85 0.91 1.56 5.54 3.53 0.88 1.21 1.17 2.50 
4 7.80 5.55 7.16 9.06 11.20 5.07 1.24 7.53 9.96 8.29 
5 24.10 8.61 4.68 8.93 21.64 - 2.93 16.24 2.05 4.05 
6 5.12 - 8.46 7.60 - 13.99 5.91 - - 31.55 
7 9.14 15.66 11.34 18.85 41.05 19.64 5.98 25.12 8.93 18.08 
8 6.60 - - 26.80 9.38 - 1.35 - 9.17 8.72 
9 4.20 1.08 2.83 8.90 8.77 6.05 0.89 2.61 1.72 2.25 
10 5.20 0.34 0.17 9.20 9.44 7.43 0.14 2.77 0.60 2.50 
Dox 0.02 0.01 0.20 0.04 0.01 0.18 0.02 0.09 0.03 0.01 
GI50: (growth inhibitory activity) the drug concentration that reduces cellular growth by 50%; Dox: 
Doxorubicin; (-): GI50 value not presented. 
Table 2. TGI and LC50 (values in parentheses) in µg/mL for compounds 2–10 in ten tumor 
cell lines. 
Cancer Cell Lines 
 U251 MCF-7 NCI/ADR-RES 786-0 NCI-H460 PC-3 OVCAR-3 HT-29 K-562 HaCaT 
2 
4.10 
(29.19) 
5.12 
(-) 
3.62 
(30.26) 
8.62 
(31.36) 
7.97 
(34.92) 
13.10 
(-) 
1.59 
(33.69) 
8.52 
(30.60) 
5.67 
(-) 
16.74 
(-) 
3 
6.13 
(31.36) 
2.36 
(-) 
2.56 
(-) 
17.98 
(-) 
17.35 
(-) 
18.31 
(-) 
9.77 
(-) 
3.27 
(26.21) 
- 
- 
29.02 
>100 
4 - 
23.54 
(-) 
- - - - 
29.61 
(-) 
- - - 
5 - 
20.26 
(47.93) 
83.07 
(-) 
- - - 
41.52 
(-) 
48.50 
(-) 
8.98 
(-) 
18.41 
(55.32) 
6 - - - - - 
84.67 
(-) 
- - - - 
7 
64.22  
(-) 
- 
66.56 
(-) 
- - - - - 
41.76  
(-) 
- 
8 
26.07  
(-) 
- - - - - - - - - 
9 
14.58 
(41.26) 
5.06 
(-) 
15.86 
(-) 
24.68 
(-) 
19.43 
(42.67) 
18.09 
(56.99) 
13.62 
(58.99) 
13.74 
(58.99) 
11.35 
(58.99) 
16.53  
(-) 
10 
16.40 
(30.43) 
3.20 
(20.24) 
2.33 
(19.65) 
29.40 
(-) 
29.52 
(65.78) 
28.45 
(69.30) 
2.38 
(17.34) 
17.66 
(60.32) 
3.70 
(20.20) 
18.00 
(-) 
Dox 
2.68 
(-) 
2.52 
(-) 
22.42 
(-) 
0.51 
(17.82) 
3.73 
(-) 
1.03 
(7.95) 
1.47 
(-) 
26.03 
(-) 
2.60 
(20.09) 
0.77 
(-) 
TGI: the drug concentration required for total growth inhibition; LC50: the drug concentration required for 
killing 50% of cells; Dox: Doxorubicin; (-): not presented. 
Molecules 2015, 20 5364 
 
The GI50 values (growth inhibitory activity) (Table 1) refer to the drug concentration that produces a 
50% reduction of cellular growth compared with the untreated control cells. The TGI (cytostatic 
activity) and LC50 (cytotoxic activity) values (Table 2) refer to the drug concentration required for total 
growth inhibition and killing 50% of the cells, respectively. GI50 values were used to classify a 
compound’s activity as follows: inactive, >100 µM; moderate, between >10 and <100 µM; and active, 
<10 µM. 
The N'-(substituted)-arylidene galloyl hydrazide 4, which has a phenyl group attached to the galloyl 
hydrazide moiety, possesses antiproliferative activity with GI50 values ranging from 1.24 to 9.96 µM 
for nine human tumor cell lines. In particular, the compound displayed activity against the ovarian cell 
line OVCAR-3 with a GI50 value of 1.24 µM (Table 1). Derivative 5, which has a dimethylaminophenyl 
group attached to the galloyl hydrazide moiety, displayed cytotoxic efficacy against OVCAR-3  
(GI50 = 2.93 µM; TGI = 41.52 µM) and leukemia K-562 (GI50 = 2.05 µM; TGI = 8.98 µM) cell lines 
(Tables 1 and 2). Compounds 6 and 7 did not demonstrate cytotoxic efficacy in these cell lines. The 
activity against the OVCAR-3 cell line was also observed for compound 8 (GI50 = 1.35 µM), 
containing the p-hydroxyphenyl group to the galloyl hydrazide moiety. 
The introduction of the 2-thioxo-1,3,4-oxadiazol-5-yl group 9 at C-1 of the galloyl group led to 
significant cytotoxicity, with GI50 less than 8.90 µM towards all cell lines, and displayed significant 
activity against OVCAR-3 (GI50 = 0.89 µM), MCF-7 (GI50 = 1.08 µM), K-562 (GI50 = 1.72 µM), 
HaCaT (GI50 = 2.25 µM), HT-29 (GI50 = 2.61 µM), and NCI/ADR/RES (GI50 = 2.83 µM) cell lines. 
The 2-methylthio analogue 10 showed an increase in antiproliferative activity, with particular effectiveness 
against OVCAR-3 (GI50 = 0.14 µM, TGI = 2.38 µM, LC50 = 17.34 µM), MCF-7 (GI50 = 0.34 µM,  
TGI = 3.20 µM, LC50 = 20.24 µM), K-562 (GI50 = 0.60 µM, TGI = 3.70 µM, LC50 = 20.20 µM) and 
NCI/ADR/RES (GI50 = 0.17 µM, TGI = 2.33 µM, LC50 = 19.65 µM) cell line (Tables 1 and 2). 
In addition, the precursor compound methyl gallate 2 exhibited potent, broad-spectrum antitumor 
activity with GI50 values < 1.0 µM against all human tumor cell lines tested, with GI50 (TGI) values 
ranging from 0.05 to 0.65 µM (1.59–16.74 µM) (Tables 1 and 2). The intermediary, galloyl hydrazide 
3, also showed significant activity, with GI50 values in the range of 0.85–5.54 µM for all cell lines 
tested, and displayed cytotoxic efficacy against MCF-7 breast (GI50 = 0.85 µM, TGI = 2.36 µM), 
NCI/ADR-RES multiple drug resistant breast (GI50 = 0.91 µM, TGI = 2.56 µM) and OVCAR-3 
ovarian (GI50 = 0.88 µM, TGI = 9.77 µM) cells (Tables 1 and 2). Methyl gallate is a derivative of 
gallic acid that has been extensively investigated for important biological properties such as 
antioxidant, anti-inflammatory, antimicrobial and antitumor activities by inhibiting tumor infiltration 
of CD4+CD25+ regulatory T cell and glioma cells [19,33–37]. However, the antitumor activity of this 
compound has not been extensively examined in other cancer cells. We examined the effect of methyl 
gallate in ten human tumor cell lines and observed selective cytotoxicity in all cell lines tested. 
An analysis of the relationship between the GI50 data and the effects of the substitutions in the 
aromatic ring at the N'-(substituted)-arylidene galloyl hydrazide with electron-withdrawing and 
electron-donating substituents 5–8 did not display enhanced activity compared with the phenyl 
substituent 4, which demonstrated a pronounced effect on cell line proliferation. These results suggest 
that the electronic features of the various substituents affect how easily the drug can interact with 
biological molecules. Regarding the relationship between the 1,3,4-oxadiazolyl derivatives, compound 
10 displayed the highest antiproliferative activity compared to the corresponding precursor 9, 
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exhibiting selectivity for four cell lines. Substitution by ester, hydrazine and 1,3,4-oxadiazolyl moiety 
side chains in compounds 2, 3, 9 and 10 resulted in a reduction in the percentage of growth inhibition, 
thereby indicating the importance of these side chain groups. 
The anthracyclins doxorubicin (DOX) and daunorubicin (DNR) are among the most useful 
antibiotic, antitumor natural isolates from a species of the bacteria Streptomyces for the treatment of 
breast cancer, solid tumors and leukemia [38–42]. The mechanism of action is complex. Briefly, 
doxorubicin interferes with DNA replication by intercalation into DNA molecules, thus inhibiting the 
biosynthesis of DNA, RNA and protein as well as the induction of the free radicals inside the cell, 
leading to senescence and cell death by apoptosis or necrosis [43,44]. The compounds synthesized 
have functional groups similar to DOX, which suggests that they may act in a similar manner. Thus, 
the development of new molecular targets for antitumor therapies is directly correlated to many tumors 
that are resistant to therapeutic strategies and side effects. The main side effect of DOX is cardiac 
insufficiency, which is caused by the production of free radicals in the myocardium. In clinical 
research, chemotherapy resistance has been identified as a serious problem when the concentrations of 
chemotherapy drugs reach toxic and harmful doses for killing tumors. 
2.3. Lipinski’s Rule of Five 
The present study focused on the antiproliferative activity and synthesis of structurally modified 
galloyl derivatives, but we also explored the bioavailability of the synthesized derivatives, which is of 
importance for further development of drugs based upon these substances and their analogues.  
Drug-likeness is a promising paradigm to identify a balance that influences the pharmacodynamic and 
pharmacokinetic properties of a compound that ultimately optimizes its absorption, distribution, 
metabolism and excretion (ADME) in the human body [45]. 
These parameters were tentatively assessed using theoretical calculations following Lipinski’s rule 
of five, which establishes that the absorption or permeation of an orally administered compound is 
more likely to be efficient if the drug satisfies the established criteria: molecular weight (MW) ≤ 500 Da, 
log P ≤ 5, H-bond donors (HBD) ≤ 5 and H-bond acceptors (HBA). 
Our results (Table 3) revealed that derivatives 2, 4–10, presented lipophilicities less than 5, with 
values between 0.34 and 1.94. Galloyl hydrazide (3) showed lipophilicity, Log P = −0.94, which is not 
in violation of Lipinski’s rules. To further evaluate the drug-likeness, the rules have spawned many 
extensions, such as the partition coefficient, Log P in −0.4 to +5.6 ranges [46]. All derivatives have a 
number of hydrogen bond acceptors (HBA) (n-ON = 5–9), and their molecular weights were smaller 
than 500 (184.15 > MW < 317.26), which is in agreement with Lipinski’s rules. With the exception of 
the hydrazide 3, they all have a number of hydrogen bond donors (HBD) (n-OHNH = 6), violating one 
of the Lipinski’s rules. The calculated percent absorption (%ABS) of all derivatives ranged between 
57.95% and 78.98%, indicating that these compounds have good permeability in the cellular 
membrane. Other rules include the number of rotatable bonds, indicating the flexibility of the 
molecule, the volume and the polar surface area. The topological polar surface area (TPSA) is 
recognized as a good indicator of drug absorption in the intestine (TPSA less than 140 Angstroms 
squared [Å2]) and blood-brain barrier penetration (TPSA less than 60 Å2). The compounds exhibit 
computational TPSA values between 86.99 and 122.37 Å2 and have good intestinal absorption except 
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6 (147.97 Å2). However, the derivatives do not have adequate blood-brain barrier penetration, as the 
TPSA values are more than 60 Å2. 
The empirical conditions to satisfy Lipinski’s rule and to manifest a good oral bioavailability 
involve a balance between the solubility of a compound and its ability to diffuse passively through the 
different biological barriers. Compounds with high solubility are more easily metabolized and 
eliminated from the organism, thus leading to a lower probability of adverse effects and 
bioaccumulation. The compound 2 (Log S = −0.87) presented good solubility, thus encouraging its use 
as a precursor to produce new drugs that have better absorption. 
Table 3. Lipinski’s rule and %ABS, TPSA, Log S for compounds 2–10. 
   Lipinski’s Parameters 
Comp. %ABS 
TPSA a 
(Å2) 
nHBA a 
(nON) 
nHBD a 
(nOHNH) 
Log P a MW a n violations a Log S b 
2 78.98 86.99 5 3 0.85 184.15 0 −0.87 
3 69.04 115.80 6 6 −0.94 184.15 1 −1.09 
4 73.75 102.15 6 4 1.84 272.26 0 −2.83 
5 72.64 105.38 7 4 1.94 315.33 0 −2.87 
6 57.95 147.97 9 4 1.80 317.26 0 −3.47 
7 70.57 111.38 7 4 1.89 302.29 0 −2.85 
8 66.78 122.37 7 5 1.36 288.26 0 −2.54 
9 73.63 102.51 6 4 0.34 226.21 0 −2.10 
10 74.63 99.61 6 3 1.27 240.24 0 −3.07 
a www.molinspiration.com [47]; b www.organic-chemistry.org/prog/peo [48]; %ABS = 109 − 0.345 × TPSA; 
Number hydrogen bond acceptor (NO) = nHBA ≤ 10; Number hydrogen bond donors (OHNH) = nHBD ≤ 5; 
MW ≤ 500; Octanol-water partition coefficient = Log P < 5; Solubility = Log S between −1 and −5. 
3. Experimental Section 
3.1. Chemistry 
3.1.1. General 
1H- and 13C-NMR spectra were recorded at 300 MHz and 75 MHz, respectively, using a model 
Mercury plus BB spectrometer (Varian, Palo Alto, CA, USA). Mass spectra (MS) were recorded in a 
Focus-DSQ II spectrometer (Thermoelectron Corporation, Austin, TX, USA). IR spectra were 
recorded on a model MB-100 spectrometer (BOMEM, Quebec, CA, USA). For TLC, precoated plates 
(silica gel 60 G254, Macherey-Nagel, Duren, GER) were used. All reagents were purchased from 
commercial suppliers. 
3.1.2. Galloyl hydrazide (3) 
Briefly, 80% hydrazine hydrate (1.8 mL, 48.2 mmol) was added to a solution of methyl gallate (2) 
(2.5 g, 2.97 mmol) that was previously prepared by esterification of commercial gallic acid (1) in 
ethanol (30 mL). This mixture was heated at reflux for 60 h, when TLC analysis indicated the end of 
the reaction. Then, the media was poured on ice, and the resulting precipitate was filtered, affording 
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the title compound 3 (1.85 g, 74%) as pale white powder, mp 164–167 °C (MeOH); mp 167 °C [32]; 
IR (KBr) νmax (cm−1): 3365–3284 (O-H, N-H), 1623 (C=O), 1509–1303 (C=C), 1260 (C-O); 1H-NMR 
(DMSO-d6): δH 6.77 (s, 2H); 8.59 (NH); 9.32 (OH). 13C-NMR (DMSO-d6): δC 106.5, 123.9, 136.2, 
145.4, 166.4. MS m/z (%): 185 (MH+, 12), 153 (100), 126 (42). 
3.1.3. General Procedure for the Preparation of N'-(Substituted)-arylidene galloyl hydrazides 4–8 
A solution of galloyl hydrazide (3) (0.28 g, 1 mmol) in water (10 mL) containing two drops of conc. 
H2SO4 was heated at reflux for 0.5 h until complete dissolution. Then, aromatic aldehydes 
(benzaldehyde, 4-N-dimethylaminobenzaldehyde, 4-nitrobenzaldehyde, 4-methoxybenzaldehyde and 
4-hydroxybenzaldehyde, 1.5 mmol) in EtOH (3 mL) were added to the solution, which was then 
heated at reflux for 48 h. The mixtures were poured into cold water and neutralized with 10% aqueous 
NaHCO3. The precipitates were collected by filtration, recrystallized and dried, yielding the 
compounds 4–8 in 74%–83% yields. 
N'-(Benzylidene)galloyl hydrazide (4). White powder (0.20 g, 71%), mp 170–173 °C (MeOH); mp 
170–172 °C [32]; IR (KBr) νmax (cm−1): 3362–3270 (O-H, N-H), 1630 (C=O), 1518 (C=C), 1264 (C-O); 
1H-NMR (CD3OD): δH 7.30–7.68 (5H, m), 7.70 (2H, s), 8.65 (1H, s, N'=CH). 13C-NMR (CD3OD): δC 
115.4, 126.3, 128.7, 128.8, 131.0, 133.9, 140.4, 145.2, 148.7, 162.5. MS m/z (%): 272 (MH+, 8), 153 
(100), 126 (30). 
N'-(4-Dimethylaminobenzylidene)galloyl hydrazide (5). White powder, (0.22 g, 78%) mp 174–178 °C 
(MeOH); mp 175–178 °C [32]; IR (KBr) νmax (cm−1): 3325 (O-H, N-H), 1661 (C=O), 1520 (C=C), 
1264 (C-O); 1H-NMR (CD3OD): δH 3.03 (6H, s), 6.93 (2H, d, J = 8.7 Hz), 7.68 (2H, s), 7.78 (2H, d,  
J = 8.7 Hz), 8.36 (1H, s, N'=CH). 13C-NMR (CD3OD): δC 40.3, 111.9, 114.1, 125.9, 129.8, 130.4, 
141.4, 146.2, 149.4, 151.2, 162.6. MS m/z (%): 315 (MH+, 12), 153 (100), 126 (33). 
N'-(4-Nitrobenzylidene)galloyl hydrazide (6). Pale yellow powder (0.24 g, 83%); mp 171–174 °C 
(MeOH); mp 171–172 °C [32]; IR (KBr) νmax (cm−1): 3422–3280 (O-H, N-H), 1665 (C=O), 1520 
(C=C), 1264 (C-O); 1H-NMR (CD3OD): δH 6.98 (2H, s), 7.94 (2H, d, J = 8.5 Hz), 7.28 (2H, d, J = 8.5 Hz), 
8.49 (1H, s, N'=CH), 9.19 (OH, NH). 13C-NMR (CD3OD): δC 116.3, 122.8, 124.1, 127.8, 137.3, 141.0, 
143.9, 145.6, 147.6, 163.4; MS m/z (%): 317 (MH+, 10), 153 (100), 126 (21). 
N'-(4-Methoxybenzylidene)galloyl hydrazide (7). Pale white powder (0,23 g, 80%), mp 170–172 °C 
(MeOH); mp 171–173 °C [32]; IR (KBr) νmax (cm−1): 3410–3260 (O-H, N-H), 1668 (C=O), 1520 
(C=C), 1262 (C-O); 1H-NMR (CD3OD): δH 3.87 (3H, s, OCH3), 7.00 (2H, s), 7.70 (2H, d, J = 8.3 Hz), 
6.80 (2H, d, J = 8.3 Hz), 8.58 (1H, s, N'=CH). 13C-NMR (CD3OD): δC 55.6, 110.2, 114.4, 126.5, 
128.6, 130.0, 136.8, 145.5, 146.6, 160.5, 161.6; MS m/z (%): 302 (MH+, 31), 153 (100), 126 (17). 
N'-(4-Hydroxybenzylidene)galloyl hydrazide (8). White powder (0,20 g, 78%), mp 170–173 °C 
(MeOH); mp 172–174 °C [32]; IR (KBr) νmax (cm−1): 3418–3266 (O-H, N-H), 1668 (C=O), 1571 
(C=C), 1260 (C-O); 1H-NMR (CD3OD): δH 7.12 (2H, s), 7.34 (2H, d, J = 7.8 Hz), 6.60 (2H, d, J = 7.8 
Hz), 8.66 (1H, s, N'=CH). 13C-NMR (CD3OD): δC 115.6, 114.8, 125.5, 128.7, 132.0, 136.8, 147.5, 
147.6, 158.5, 160.6; MS m/z (%): 288 (MH+, 18), 153 (100), 126 (44). 
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3.1.4. Galloyl-2-thioxo-1,3,4-oxadiazole (9) 
Carbon disulfide (0.8 mL, 5 mmol) and potassium hydroxide (0,213 g, 1 mmol) were added to a 
solution of galloyl hydrazide (3) (0.456 g, 1 mmol) in EtOH (10 mL) at 0 °C. The resulting solution 
was heated at reflux for 48 h. The solvent was evaporated, and the residue was dissolved in water and 
acidified with a dilute solution of HCl. The solid obtained was filtered and recrystallized to give the 
title compound 9 (0.36 g, 80%) as a white powder, mp 168–170 °C (MeOH); IR (KBr) νmax (cm−1): 
3370–3280 (O-H), 1595–1430 (C=C), 1245 (C-S), 1168 (C-O-C); 1H-NMR (CD3OD): δH 6.82 (2H, s), 
9.05 (OH, NH); 13C-NMR (CD3OD): δC 105.0, 112.0, 137.6, 146.5, 161.1, 176.9. MS m/z (%): 226 
(MH+, 12), 150 (100), 77 (28). 
3.1.5. Galloyl-2-methylthio-1,3,4-oxadiazole (10) 
To a solution of galloyl-2-thioxo-1,3,4-oxadiazole (9) (0.20 g, 0.6 mmol) in anhydrous THF (10 mL) 
was to added K2CO3 (0.14 g, 0.6 mmol). The resulting solution was stirred at room temperature for 1 h. 
Methyl iodide (0.19 mL, 0.8 mmol) was then added, and the mixture was stirred for an additional 48 h. 
The solvent was removed, and the residue obtained was crystallized to give the title compound 10 
(0.1192 g, 60%), as a brown powder, mp 166–168 °C (MeOH); IR (KBr) νmax (cm−1): 3376 (O-H,  
N-H), 1668 (C=O), 1565–1430 (C=C), 1170 (C-O-C), 720 (C-S-C); 1H-NMR (CD3OD): δH 2.80 (3H, 
s, SCH3); 7.00 (2H, s); 9.62 (OH). 13C-NMR (CD3OD): δC 16.2, 110.2, 112.4, 136.6, 146.8, 162.2, 
160.4; MS m/z (%): 240 (MH+, 8), 150 (100), 91 (28). 
3.2. Anticancer Assay in Vitro 
The synthesized compounds were assessed in the following ten human tumor cell lines from various 
tissues kindly provide by the National Cancer Institute (Frederick, MD, USA): U251 (glioma, CNS), 
MCF-7 (breast), NCI-ADR/RES (breast expressing the multiple drug resistance phenotype), 786-0 
(renal), NCI-H460 (lung, non-small cells), PC-3 (prostate), OVCAR-3 (ovarian), HT-29 (colon),  
K-562 (leukemia) and HaCaT (keratinocytes). Stock cultures were grown in media containing 5 mL of 
RPMI 1640 (Gibco BRL) supplemented with 5% fetal bovine serum. Gentamicin (50 mg/mL) was 
added to the experimental cultures. Cells in 96-well plates (100 µL cells/well) were exposed to sample 
concentrations in DMSO/RPMI (0.25, 2.5, 25, and 250 µg/mL) at 37 °C and 5% CO2 for 48 h. The 
final DMSO concentration did not affect cell viability. Next, cells were fixed with 50% trichloroacetic 
acid, and cell proliferation was determined by spectrophotometric quantification (540 nm) of cellular 
protein content employing the sulforhodamine B assay [49]. Doxorubicin (0.025–25 µg/mL) was used 
as a positive control. Three measurements were obtained: first at time point zero (T0, at the beginning 
of incubation) and then 48 h post-incubation for both the compound-free (C) and tested (T) cells. Cell 
proliferation was determined using the equation 100 × [(T − T0)/C − T0]. A cytostatic effect was 
observed when T ≥ T0, while a cytocidal effect occurred when T < T0. The experiments were 
performed in triplicate. 
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3.3. In Silico Study 
An in silico computational study of the synthesized compounds 2–10 was performed to determine 
Lipinski’s rules, topological polar surface area (TPSA) and percentage of absorption (%ABS). 
Calculations were performed using Molinspiration online property calculation toolkit software [47] 
and OSIRIS property explorer software [48]. The percentage of absorption was estimated using the 
following equation: %ABS = 109 − [0.345 × TPSA]. Lipinski’s rule states that an orally active drug 
generally has no more than one violation of the following criteria [50]: 
(I) hydrogen bond donors ≤ 5 (OH and NH groups); 
(II) hydrogen bond acceptors ≤ 10 (N and O atoms); 
(III) molecular weight < 500; 
(IV) calculated logP < 5. 
4. Conclusions 
The results suggest that synthetic derivatives of N'-(substituted)-arylidenegalloyl hydrazide do not 
have a very strong synergistic effect in the inhibition of cancer cell proliferation compared with methyl 
gallate (2), galloyl hydrazide (3) and 1,3,4-oxadiazolyl derivatives 9 and 10. These compounds showed 
higher inhibition effect against ovarian (OVCAR-3) cells. Computational drug-likeness and TPSA 
calculations revealed that the compounds show good intestinal absorption. Finally, the in silico study 
identified these derivatives as potential new drug candidates. More detailed studies with other models, 
such in vivo assays, are essential for the characterization of these derivatives as anticancer agents. 
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